Related Experiment Video

Updated: Jun 21, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

Angiotensin-converting enzyme and angiotensinogen gene polymorphism in hypertrophic cardiomyopathy

Hideaki Kawaguchi1

  • 1Department of Pathophysiology and Laboratory Medicine, Hokkaida University Graduate School of Medicine, Japan.

Experimental and Clinical Cardiology
|July 31, 2009
PubMed

Insights

Genetic factors in the renin-angiotensin system contribute to hypertrophic cardiomyopathy (HCM). Angiotensinogen gene variants increase the risk of cardiac hypertrophy, particularly in sporadic cases of HCM.

Area of Science:

  • Cardiovascular Genetics
  • Molecular Cardiology
  • Human Genetics

Background:

  • Hypertrophic cardiomyopathy (HCM) is a complex cardiac disease with a significant genetic component.
  • The renin-angiotensin system (RAS) plays a crucial role in cardiovascular regulation and has been implicated in cardiac hypertrophy.

Purpose of the Study:

  • To investigate the association between genetic polymorphisms in the renin-angiotensin system and hypertrophic cardiomyopathy.
  • To determine if specific gene variants predispose individuals to developing HCM, especially in sporadic forms.

Main Methods:

  • A case-control study involving 96 HCM patients, 105 unaffected relatives, and 160 healthy controls.
  • Genotyping for angiotensinogen (AGT) T235 polymorphism and angiotensin-converting enzyme (ACE) insertion/deletion polymorphism.

Main Results:

  • The T allele of the angiotensinogen T235 variant was more frequent in sporadic HCM (SHCM) patients compared to unaffected relatives.
  • The angiotensinogen T235 variant was associated with an approximately twofold increased risk of cardiac hypertrophy in HCM.
  • The D allele of the ACE gene insertion/deletion polymorphism was more frequent in SHCM than in familial HCM (FHCM).

Conclusions:

  • Genetic variations in the renin-angiotensin system, specifically angiotensinogen and angiotensin-converting enzyme gene polymorphisms, are contributing factors to hypertrophic cardiomyopathy.
  • Genetic predisposition plays a significant role in the development of HCM, particularly in solitary cases.

Keywords:
Angiotensin-converting enzymeAngiotensinogenCardiac hypertrophyCardiomyopathyGene polymorphism

More Related Videos

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...